vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Applied Therapeutics, Inc. (APLT). Click either name above to swap in a different company.
Aeluma, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.0M, roughly 1.3× Applied Therapeutics, Inc.). Aeluma, Inc. runs the higher net margin — -145.7% vs -1899.0%, a 1753.3% gap on every dollar of revenue. On growth, Applied Therapeutics, Inc. posted the faster year-over-year revenue change (719.7% vs -21.1%).
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
ALMU vs APLT — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.0M |
| Net Profit | $-1.9M | $-19.0M |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | -1675.8% |
| Net Margin | -145.7% | -1899.0% |
| Revenue YoY | -21.1% | 719.7% |
| Net Profit YoY | 36.0% | 72.3% |
| EPS (diluted) | $-0.11 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.4M | $1.0M | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $-1.0K | ||
| Q2 24 | — | $144.0K | ||
| Q1 24 | — | $190.0K | ||
| Q4 23 | — | $-667.0K |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.5M | $-19.0M | ||
| Q2 25 | — | $-21.3M | ||
| Q1 25 | — | $-21.8M | ||
| Q4 24 | — | $44.0M | ||
| Q2 24 | — | $2.9M | ||
| Q1 24 | — | $-83.9M | ||
| Q4 23 | — | $-37.7M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | -163.6% | — | ||
| Q3 25 | -116.1% | -1675.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3302300.0% | ||
| Q2 24 | — | -14194.4% | ||
| Q1 24 | — | -11101.6% | ||
| Q4 23 | — | 3149.3% |
| Q4 25 | -145.7% | — | ||
| Q3 25 | -107.8% | -1899.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4400700.0% | ||
| Q2 24 | — | 2012.5% | ||
| Q1 24 | — | -44177.9% | ||
| Q4 23 | — | 5649.0% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.09 | $-0.13 | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.52 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.67 | ||
| Q4 23 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $11.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $-561.0K |
| Total Assets | $42.6M | $34.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | — | ||
| Q3 25 | $25.9M | $11.9M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $50.8M | ||
| Q4 24 | — | $79.4M | ||
| Q2 24 | — | $122.2M | ||
| Q1 24 | — | $146.5M | ||
| Q4 23 | — | $49.9M |
| Q4 25 | $40.8M | — | ||
| Q3 25 | $40.9M | $-561.0K | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $57.0M | ||
| Q2 24 | — | $72.4M | ||
| Q1 24 | — | $67.3M | ||
| Q4 23 | — | $-17.1M |
| Q4 25 | $42.6M | — | ||
| Q3 25 | $42.7M | $34.4M | ||
| Q2 25 | — | $37.3M | ||
| Q1 25 | — | $56.9M | ||
| Q4 24 | — | $86.7M | ||
| Q2 24 | — | $127.8M | ||
| Q1 24 | — | $151.2M | ||
| Q4 23 | — | $54.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-18.4M |
| Free Cash FlowOCF − Capex | $-282.0K | — |
| FCF MarginFCF / Revenue | -22.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | — | ||
| Q3 25 | $-815.0K | $-18.4M | ||
| Q2 25 | — | $-20.3M | ||
| Q1 25 | — | $-28.6M | ||
| Q4 24 | — | $-19.5M | ||
| Q2 24 | — | $-22.6M | ||
| Q1 24 | — | $-18.9M | ||
| Q4 23 | — | $-17.0M |
| Q4 25 | $-282.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | -22.2% | — | ||
| Q3 25 | -74.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 15.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.44× | ||
| Q2 24 | — | -7.80× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
